Literature DB >> 25738454

GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7.

Jacqueline A Koehler1, Laurie L Baggio1, Bernardo Yusta1, Christine Longuet1, Katherine J Rowland2, Xiemin Cao1, Dianne Holland1, Patricia L Brubaker2, Daniel J Drucker3.   

Abstract

Glucagon-like peptide-1 (GLP-1) secreted from enteroendocrine L cells promotes nutrient disposal via the incretin effect. However, the majority of L cells are localized to the distal gut, suggesting additional biological roles for GLP-1. Here, we demonstrate that GLP-1 receptor (GLP-1R) signaling controls mucosal expansion of the small bowel (SB) and colon. These actions did not require the epidermal growth factor (EGF) or intestinal epithelial insulin-like growth factor (IGF1) receptors but were absent in Glp1r(-/-) mice. Polyp number and size were increased in SB of exendin-4-treated Apc(Min/+) mice, whereas polyp number was reduced in SB and colon of Glp1r(-/-):Apc(Min/+) mice. Exendin-4 increased fibroblast growth factor 7 (Fgf7) expression in colonic polyps of Apc(Min/+) mice and failed to increase intestinal growth in mice lacking Fgf7. Exogenous exendin-4 and Fgf7 regulated an overlapping set of genes important for intestinal growth. Thus, gain and loss of GLP-1R signaling regulates gut growth and intestinal tumorigenesis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25738454     DOI: 10.1016/j.cmet.2015.02.005

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  38 in total

1.  Novel approaches to treating type 2 diabetes.

Authors:  Michael A Nauck
Journal:  Diabetologia       Date:  2015-12-04       Impact factor: 10.122

2.  Oxaliplatin reverses the GLP-1R-mediated promotion of intrahepatic cholangiocarcinoma by altering FoxO1 signaling.

Authors:  Bendong Chen; Wenyan Zhou; Wenchao Zhao; Peng Yuan; Chaofeng Tang; Genwang Wang; Junzhi Leng; Jinlong Ma; Xiaowen Wang; Yongfeng Hui; Qi Wang
Journal:  Oncol Lett       Date:  2019-06-19       Impact factor: 2.967

3.  Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors.

Authors:  Phyo T Htoo; John B Buse; Mugdha Gokhale; M Alison Marquis; Virginia Pate; Til Stürmer
Journal:  Eur J Clin Pharmacol       Date:  2016-05-10       Impact factor: 2.953

4.  Incretin-based therapies: where will we be 50 years from now?

Authors:  Juris J Meier; Michael A Nauck
Journal:  Diabetologia       Date:  2015-05-21       Impact factor: 10.122

Review 5.  Discovery, characterization, and clinical development of the glucagon-like peptides.

Authors:  Daniel J Drucker; Joel F Habener; Jens Juul Holst
Journal:  J Clin Invest       Date:  2017-12-01       Impact factor: 14.808

Review 6.  Cell fate specification and differentiation in the adult mammalian intestine.

Authors:  Joep Beumer; Hans Clevers
Journal:  Nat Rev Mol Cell Biol       Date:  2020-09-21       Impact factor: 94.444

Review 7.  Enteroendocrine cells-sensory sentinels of the intestinal environment and orchestrators of mucosal immunity.

Authors:  J J Worthington; F Reimann; F M Gribble
Journal:  Mucosal Immunol       Date:  2017-08-30       Impact factor: 7.313

Review 8.  Islet α cells and glucagon--critical regulators of energy homeostasis.

Authors:  Jonathan E Campbell; Daniel J Drucker
Journal:  Nat Rev Endocrinol       Date:  2015-04-07       Impact factor: 43.330

Review 9.  Environmental Factors, Gut Microbiota, and Colorectal Cancer Prevention.

Authors:  Mingyang Song; Andrew T Chan
Journal:  Clin Gastroenterol Hepatol       Date:  2018-07-18       Impact factor: 11.382

Review 10.  Unintended Effects of GPCR-Targeted Drugs on the Cancer Phenotype.

Authors:  Abigail C Cornwell; Michael E Feigin
Journal:  Trends Pharmacol Sci       Date:  2020-10-22       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.